Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100,000

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2026

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

Gardasil 9

"GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.~GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11."

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Karolinska Institutet

OTHER

collaborator

Center for Family Health Research/Projet San Francisco

UNKNOWN

collaborator

ELEKTA Foundation

UNKNOWN

lead

Rwanda Biomedical Centre

OTHER

NCT06536855 - Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda | Biotech Hunter | Biotech Hunter